lercanidipine orion 20 mg
orion corporation - espoo - lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg
lercanidipine orion 10 mg
orion corporation - espoo - lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg
cipramil 10 mg
h. lundbeck a/s - citalopramhydrobromid - tablett, filmdrasjert - 10 mg
cipramil 20 mg
h. lundbeck a/s - citalopramhydrobromid - tablett, filmdrasjert - 20 mg
enalapril/lercanidipine krka 20 mg / 10 mg
krka sverige ab - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg / 10 mg
enalapril/lercanidipine krka 10 mg / 10 mg
krka sverige ab - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg / 10 mg
zanipress 10 mg / 10 mg
recordati ireland limited - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg / 10 mg
zanipress 20 mg / 10 mg
recordati ireland limited - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg / 10 mg
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
cerdelga
sanofi b.v. - eliglustat - gaucher sykdom - andre alimentary tract and metabolism products, - cerdelga angis for den langsiktige behandlingen voksne pasienter med gaucher sykdom type 1 (gd1), som er cyp2d6 dårlig metabolisers (pms), middels metabolisers (ims) eller omfattende metabolisers (ems).